PALISADE BIO, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
PALISADE BIO, INC. (PALI) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-20
- PALISADE BIO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -0.30%, a 200.00% decline from fiscal 2024.
- PALISADE BIO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.30%.
- PALISADE BIO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2020 was 26.00%, a 9.72% decline from fiscal 2019.
- PALISADE BIO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2019 was 28.80%, a 46.57% decline from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.30% 10-K · filed 2026-03-20 | |
| 2024-12-31 | 0.30% 10-K · filed 2026-03-20 | |
| 2020-12-31 | 26.00% 10-K · filed 2021-03-22 | |
| 2019-12-31 | 28.80% 10-K · filed 2021-03-22 | |
| 2018-12-31 | 53.90% 10-K · filed 2020-03-27 | |
| 2017-12-31 | 9.60% 10-K · filed 2019-03-22 | 5.80% 10-K · filed 2018-04-02 |
| 2016-12-31 | -2.60% 10-K · filed 2018-04-02 | |
| 2015-12-31 | 0.90% 10-K · filed 2017-03-23 | 1.40% 10-K · filed 2016-03-14 |
| 2014-12-31 | 8.30% 10-K · filed 2016-03-14 | |
| 2013-12-31 | 9.50% 10-K · filed 2016-03-14 | |
| 2012-12-31 | -0.90% 10-K · filed 2015-03-16 | |
| 2011-12-31 | 1.40% 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |